Analgesic formulations and methods for reduced postoperative nausea and vomiting and enhanced postoperative pain relief
View Patent ↗A multimodal anti-emetic anesthetic/analgesic formulation for pain control not limited to postoperative pain control is described herein. The opioid-free/sparing anesthetic/analgesic formulation comprises a local anesthetic, an N-methyl-D-aspartate (NMDA) receptor antagonist, and a cyclooxygenase (COX) inhibitor such as Bupivacaine Hydrochloride, Ketamine Hydrochloride, and Ketorolac Tromethamine, which is effective to significantly reduce postoperative nausea and vomiting and enhance postoperative pain relief as compared to existing prior art anesthetics/analgesics. The formulation is administered to a mammal in need of anesthesia/analgesia and can be used as a preemptive and preventative multimodal analgesic. The formulation may have a buffer to enhance its shelf life and improve pharmacokinetics. The formulation may further comprise an alpha agonist, a steroid, a Transient Receptor Potential Channel agonist or antagonist, a beta-lactam antibiotic, a protein kinase inhibitor, a competitive or non-competitive glycine or glutamate antagonist, a glutamate or glycine inhibitor, a cyclooxygenase 3 inhibitor, or combinations thereof.
1. A method of treating pain, said method comprising administering, by subcutaneous injection, intramuscular injection, intrafascial injection, or intradermal injection, an effective amount of a formulation to a mammal in need of such treatment, the formulation comprising about 0.01%-0.5% of a local anesthetic comprising bupivacaine or ropivacaine, about 0.01-3.0 mg/cc of an N-methyl-D-aspartate (NMDA) receptor antagonist comprising MgSO 4 or ketamine, and about 0.01-1.2 mg/cc of a cyclooxygenase (COX) inhibitor comprising meloxicam or ketorolac.
2. The method of claim 1 , wherein the formulation further comprises an alpha agonist, a steroid, a Transient Receptor Potential channel agonist or antagonist, a beta-lactam antibiotic, a protein kinase inhibitor, a competitive or non-competitive glycine or glutamate antagonist, a glutamate or glycine inhibitor, a cyclooxygenase 3 inhibitor, vancomycin, tranexamic acid, or combinations thereof.
3. The method of claim 1 , wherein the formulation further comprises a Transient Receptor Potential Vanilloid (TRPV) receptor agonist or antagonist, acetaminophen, paracetamol, dexamethasone, a corticosteroid, cephazolin, vancomycin, tranexamic acid, or a combination thereof.
4. The method of claim 1 , wherein the local anesthetic comprises Ropivacaine Hydrochloride.
5. The method of claim 1 , wherein the NMDA receptor antagonist comprises Magnesium Sulfate.
6. The method of claim 1 , wherein the COX inhibitor comprises Meloxicam.
7. The method of claim 1 , wherein the formulation is administered via a pump or a syringe.
8. The method of claim 1 , wherein the formulation is administered to a site prior to a needle insertion, an incision, or other medical, veterinarian or dental procedure.
9. The method of claim 1 , wherein the formulation is administered in a single injection to the subject.
10. The method of claim 1 , wherein the formulation is administered as a continuous infusion rate of about 0.1 mL to 100 mL per hour to the subject.
11. The method of claim 1 , wherein the formulation comprises about 0.01%-0.5% of ropivacaine, about 0.01-3.0 mg/cc of MgSO 4 , and about 0.01-1.2 mg/cc of meloxicam.
12. The method of claim 11 , further comprising administering an alpha agonist to the mammal.
13. The method of claim 12 , wherein the alpha agonist is epinephrine.
14. The method of claim 1 , wherein the formulation comprises about 0.01%-0.5% of bupivacaine, about 0.01-3.0 mg/cc of ketamine, and about 0.01-1.2 mg/cc of ketorolac.
15. The method of claim 14 , further comprising administering an alpha agonist to the mammal.
16. The method of claim 15 , wherein the alpha agonist is epinephrine.